Table 2.

Univariate and multivariate analyses using Cox regression for overall survival and progression-free survival according to thyroid dysfunction and others characteristics of the cohort

	Overall survival		Progression-free survival
	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
Univariate
Sex (male)	1.07 [0.64; 1.78]	0.788	1.24 [0.78; 1.96]	0.366
Age > 70 ans	1.02 [0.64; 1.61]	0.944	0.9 [0.59; 1.36]	0.611
WHO Performance Score ≤ 1	0.42 [0; 0.69]	< 0.001	0.64 [0.4; 1.02]	0.063
Current or former smoker	1.27 [0.4; 4.02]	0.685	1.94 [0.61; 6.2]	0.261
Squamous cell carcinoma positive	0.99 [0.6; 1.62]	0.971	0.9 [0.59; 1.38]	0.638
Stade IIIB positive	0.38 [0.12; 1.19]	0.096	0.49 [0.21; 1.12]	0.089
Brain metastasis positive	0.7 [0.43; 1.13]	0.141	0.74 [0.49; 1.13]	0.164
Number of past regimens (≥ 3)	0.63 [0.38; 1.05]	0.075	0.8 [0.52; 1.23]	0.304
History of others ICI (%)	1.54 [0.56; 4.2]	0.402	1.26 [0.46; 3.44]	0.647
Radiotherapy positive	0.96 [0.63; 1.46]	0.858	1.21 [0.83; 1.75]	0.315
PD-L1 expression > 5%	1.1 [0.4; 2.97]	0.858	1.1 [0.47; 2.55]	0.825
LIPI score (poor prognosis)	1.82 [1.06; 3.13]	0.029	1.59 [0.99; 2.56]	0.056
Non-thyroid IRAEs positive	0.32 [0; 0.55]	< 0.001	0.4 [0; 0.61]	< 0.001
TD (+)	0.45 [0; 0.69]	< 0.001	0.44 [0; 0.64]	< 0.001
Multivariate
WHO Performance Score ≤ 1	0.33 [0.17; 0.64]	< 0.001	0.37 [0.2; 0.69]	0.002
Non-thyroid IRAEs positive	–	–	0.43 [0.26; 0.72]	0.001
TD (+)	0.32 [0.16; 0.62]	< 0.001	0.36 [0.21; 0.62]	< 0.001

Bold indicates p value < 0.05

ICI: immune checkpoint inhibitors; IRAEs: immune related adverse; LIPI: lung immune prognostic index; events; PD-L1: programmed cell death ligand 1; PS: performance score; TD(+): thyroid dysfunction (+) group